Skip to main content

Table 3 Supplementation duration and adherence

From: Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial

Adherence

Placebo

Vitamin D

p

Mean ± SD

Median

Range (min, max)

Mean ± SD

Median

Range (min, max)

Time on study, weeks

9.7 ± 3.5

10.5

(0, 18)

9.8 ± 3.3

10

(0, 18)

0.871

Total supplement doses administered

10.5 ± 3.5

11

(1, 19)

10.6 ± 3.3

11

(1, 17)

0.83

Total vitamin D administered, mcg

-

-

-

9469 ± 2424

9625

(875, 14000)

-

Adherence, % 2

99.2 ± 2.7

100

(84.6, 100)

99.4 ± 2.9

100

(80, 100)

0.79

Participants who received 100% of scheduled doses, n (%) 3

 

68 (91.9%)

  

69 (94.5%)

 

0.533

  1. 1 p-value for Student’s t-test for equality of means.
  2. 2 Adherence = (number of doses received divided by the number of doses scheduled) x 100. Analysis shown included participants who contributed 25(OH)D measurements beyond baseline (n = 74 and n = 73 in placebo and vitamin D groups, respectively). Adherence for participants for whom delivery specimens were available was similar: mean of 99.1% in the placebo group (n = 63) and 99.3% in the vitamin D group (n = 67). With respect to longitudinal analyses of changes in 25(OH)D over time, 206/219 serum specimens (93.5%) in the vitamin D group and 201/213 (94.4%) specimens in the placebo group were preceded by 100% dose adherence.
  3. 3 Proportions shown were calculated among participants who contributed 25(OH)D measurements beyond baseline (74 in placebo group or 73 in the vitamin D group); p value for chi-square test for proportions. Proportions in the subgroup of participants for whom delivery specimens were available were similar: 90.5% in the placebo group (n = 63) and 94.0% in the vitamin D group (n = 67).